11个省市16家医疗机构应用富马酸伏诺拉生治疗胃食管反流病的研究

Vonoprazan Fumarate in the Treatment of Gastroesophageal Reflux Disease in 16 Medical Institutions from 11 Provinces and Cities

目的:以真实世界研究为基础,探讨富马酸伏诺拉生治疗胃食管反流病的临床应用情况及诊疗特点。方法:基于2021年《医院处方分析合作项目》数据库,采用分层随机抽样的方法,抽取应用富马酸伏诺拉生或质子泵抑制剂治疗胃食管反流病的患者门诊/住院处方数据,利用SPSS 25.0软件,对患者基本信息、年就诊次数、年用药时长和单疗程用药时长进行统计学分析。结果:共纳入2021年11个省/自治区/直辖市16家医疗机构的4 136例患者处方数据,其中富马酸伏诺拉生治疗组患者641例,质子泵抑制剂治疗组患者3 495例。两组患者年龄的差异有统计学意义(P<0.05),但与年用药时长、年就诊次数、单疗程用药时长的相关性均极弱。富马酸伏诺拉生治疗组患者的年就诊次数为1(1,1)次,年用药时长为14(14,28)d,单疗程用药时长为14(14,28) d;质子泵抑制剂治疗组患者的年就诊次数为2(2,3)次,年用药时长为34(18,65)d,单疗程用药时长为28(14,40) d;富马酸伏诺拉生治疗组患者各项指标均显著低于质子泵抑制剂治疗组,差异均有统计学意义(P<0.05)。结论:对比质子泵抑制剂,应用富马酸伏诺拉生治疗胃食管反流病可显著减少患者年就诊次数,缩短年用药时长及单疗程用药时长。富马酸伏诺拉生作用快速且持久,具有更高的临床应用价值。

OBJECTIVE:To probe into the clinical application and treatment characteristics of vonoprazan fumarate in the treatment of gastroesophageal reflux disease(GERD)based on real-world study.METHODS:Based on the Hospital Prescription Analysis Collaboration database in 2021,stratified random sampling method was used to extract outpatient/inpatient prescription data from patients treated with vonoprazan fumarate or proton pump inhibitors(PPI)for the treatment of GERD,SPSS 25.0 software was used to conduct statistical analysis on patients’basic information,annual number of visits,annual medication duration and medication duration of single course.RESULTS:A total of 4136 patient’prescription data from 16 medical institutions in 11 provinces/autonomous regions/municipalities in 2021 were enrolled,including 641 patients in the vonoprazan fumarate treatment group and 3495 patients in the PPI treatment group.The difference in patients’age between two groups was statistically significant(P<0.05),while its correlations with annual medication duration,annual number of visits and medication duration of single course were extremely weak.The annual number of visits was 1(1,1)time,the annual duration of medication was 14(14,28)days,and the medication duration of single course was 14(14,28)days in the vonoprazan fumarate treatment group;the annual number of visits was 2(2,3)times,the annual duration of medication was 34(18,65)days,and the duration of a single course of medication was 28(14,40)days in the PPI treatment group;all the indexes of patients in the vonoprazan fumarate treatment group were significantly lower than those in the PPI treatment group,with statistically significant differences(P<0.05).CONCLUSIONS:Compared with PPI,proton pump inhibitors,the application of vonoprazan fumarate in the treatment of GERD can significantly reduce the annual number of visits,shorten the annual medication duration and medication duration of single course.The rapid and long-lasting effect of vonoprazan fumarate has a higher clinical application value.